Amid the global race to find effective COVID-19 treatments, an Egyptian research team has achieved a breakthrough that could reshape how middle- and low-income countries combat the virus.
The study, titled EVERST, was published on 20 October in Scientific Reports, a leading international journal under the Nature group.
According to the study, Egyptian scientists reported promising results in treating moderate COVID-19 pneumonia with safe, locally available, and affordable drugs.
The research, led by Professor Dr Mohamed Abdelsalam El-Gohary, brought together a multidisciplinary team of doctors and scientists from Egyptian and international institutions.
Over two years, the team evaluated the safety and effectiveness of four treatment regimens combining repurposed antiviral drugs — Sofosbuvir/Daclatasvir, Sofosbuvir/Ledipasvir, Ivermectin, and Hydroxychloroquine — in 310 Egyptian patients with moderate COVID-19 infections.
“Our goal was to find a practical, homegrown solution that saves lives without overburdening healthcare systems,” Professor El-Gohary told Ahram Online. “Egypt produces these medications locally, which means they are accessible and affordable for millions.”
The findings showed that two specific combinations —Sofosbuvir/Daclatasvir with Ivermectin and Sofosbuvir/Ledipasvir with Hydroxychloroquine —helped patients recover faster, shortened hospital stays, and provided remarkable protection of lung tissues on CT scans.
Patients treated with these regimens returned home significantly earlier than those who received standard care.
“This reduction in hospitalization time has major implications,” El-Gohary explained. “It not only improves patient recovery but also reduces pressure on hospitals and public health budgets, a critical factor during pandemics.”
The new combination regimen also showed improved CT scan results for pneumonia, a crucial step in preventing post-COVID complications, a growing concern worldwide.
Equally important, the study confirmed that the new treatment combinations were safe and well tolerated, with no major side effects compared with existing protocols. The only factor linked to higher mortality was advanced age.
The EVERST study, which underwent extensive international peer review before publication, reinforces Egypt’s growing role in global medical research and innovation. It also highlights the potential of repurposing affordable antiviral drugs to address emerging diseases.
source/content: english.ahram.org.eg (headline edited)
__________________

Dr Mohamed Abdelsalam El Gohary
__________
EGYPT








